Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized placebo-controlled study of CUV1647 implants in erythropoietic protoporphyria
NL-OMON31710Phase 3Active, not recruiting
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Nov 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Afamelanotide in erythropoietic protoporphyria (EPP) (2 arms), sponsored by Clinuvel Pharmaceuticals. Primary endpoints: Number of phototoxic reactions and Severity of phototoxic reactions. Started Nov 2008; status: active, not recruiting.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on NL-OMON31710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31710.